Login / Signup

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan.

Shigeki NakamuraMasashi MikamiTomoyuki HayamizuNaohiro YonemotoCamille MoyonMark GouldsonCatriona CrossanJeffrey VietriKazumasa Kamei
Published in: Expert review of vaccines (2024)
PCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60-64 years in Japan.
Keyphrases
  • cancer therapy
  • drug delivery
  • young adults